INDVL Stock Overview
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Indivior PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£14.34 |
| 52 Week High | UK£19.26 |
| 52 Week Low | UK£11.28 |
| Beta | 0.018 |
| 1 Month Change | -12.51% |
| 3 Month Change | 2.65% |
| 1 Year Change | -6.27% |
| 3 Year Change | 93.13% |
| 5 Year Change | 442.57% |
| Change since IPO | 96.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| INDVL | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0.1% | 1.7% | 2.7% |
| 1Y | -6.3% | 8.5% | 5.2% |
Return vs Industry: INDVL underperformed the UK Pharmaceuticals industry which returned 8.5% over the past year.
Return vs Market: INDVL underperformed the UK Market which returned 5.2% over the past year.
Price Volatility
| INDVL volatility | |
|---|---|
| INDVL Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: INDVL has not had significant price volatility in the past 3 months.
Volatility Over Time: INDVL's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 1,000 | Mark Crossley | www.indivior.com |
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder.
Indivior PLC Fundamentals Summary
| INDVL fundamental statistics | |
|---|---|
| Market cap | UK£1.93b |
| Earnings (TTM) | UK£3.99m |
| Revenue (TTM) | UK£897.55m |
483.5x
P/E Ratio2.2x
P/S RatioIs INDVL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INDVL income statement (TTM) | |
|---|---|
| Revenue | US$1.12b |
| Cost of Revenue | US$193.00m |
| Gross Profit | US$931.00m |
| Other Expenses | US$926.00m |
| Earnings | US$5.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 25, 2024
| Earnings per share (EPS) | 0.037 |
| Gross Margin | 82.83% |
| Net Profit Margin | 0.44% |
| Debt/Equity Ratio | 2,380.0% |
How did INDVL perform over the long term?
See historical performance and comparison